Dexcom G7 Continuous Glucose Monitoring System Will Be Available to Medicare Beneficiaries at Launch
February 13 2023 - 7:30AM
Business Wire
- U.S. Centers for Medicare & Medicaid Services has approved
coverage for Dexcom G7, the most accurate,1 easy-to-use CGM system
that helps people with diabetes gain greater control of their
health.
- Introduced to the world yesterday in a Super Bowl ad, Dexcom G7
eliminates routine fingersticks* and builds on the trusted
performance of Dexcom CGM, which is clinically proven to lower A1C
and increase time in range.2-6
- The approval of Medicare coverage for Dexcom G7 further
solidifies Dexcom as the most covered and reimbursed CGM brand on
the market.7
- People with diabetes in the US, including Medicare patients,
can visit Dexcom.com/G7 today to get started with Dexcom G7.
Dexcom, Inc. (NASDAQ:DXCM), the global leader in real-time
continuous glucose monitoring for people with diabetes, announced
today its next-generation Dexcom G7 CGM System will be covered for
Medicare beneficiaries.† Having met the category requirements for
therapeutic CGM systems set forth by the U.S. Centers for Medicare
& Medicaid Services, Dexcom G7 will be accessible to all
Medicare patients with diabetes who meet the eligibility criteria
when the system launches this Friday, Feb. 17.
“When we set out to design G7, our goal was simple: to make the
most accurate, easy-to-use CGM available for as many people with
diabetes as possible,” said Kevin Sayer, chairman, president and
CEO of Dexcom. “The approval of Medicare coverage for G7 helps us
deliver on that promise. Now Medicare patients with Type 1 and Type
2 diabetes will have access to the newest CGM technology that
offers the most reliable, simple way to help people manage their
diabetes more confidently.”
The most accurate,1 easy to use CGM available will be covered
by Medicare at launch.
With Dexcom G7, the #1 recommended CGM brand8,9 now offers the
most accurate1 and simple way to help people gain greater control
of their diabetes. Its low-profile, all-in-one wearable warms up
faster than any other CGM on the market,‡ sending real-time glucose
readings automatically to a compatible smart device§ or receiver,
no painful fingersticks* or burdensome scanning required. With an
overall MARD of 8.2%, Dexcom G7 is the most accurate CGM on the
market,1 building on the trusted performance of Dexcom CGM, which
is clinically proven to lower A1C, reduce hyper- and hypoglycemia
and increase time in range.2-6
New features with Dexcom G7:
- 60% smaller, all-in-one, discreet wearable, easier to use with
fewer components||
- 30-minute sensor warmup, fastest of any CGM system on the
market‡
- 12-hour grace period to replace finished sensors for a more
seamless transition between sessions
- Redesigned and simplified mobile app with Dexcom Clarity
integration,#
- Improved alert settings for enhanced discretion
- Redesigned receiver that is smaller, with a more vibrant,
easier to read display||
- Indicated for wear on the back of the upper arm for ages 2
years and older
Dexcom G6 features included with Dexcom
G7:
- No fingersticks,* scanning or calibration
- Real-time glucose readings sent automatically every 5 minutes
to a compatible display device§
- Integration with the world’s largest connected CGM ecosystem
(including Apple Watch, Garmin and other digital health apps)1
- Remote monitoring, enabling users to share glucose data with up
to 10 Followers**
- Proven Dexcom accuracy and performance10
- Only CGM system to offer a predictive low alert that can
recognize potentially dangerous hypo- incidences before they
occur
People with diabetes in the US, including Medicare patients,
can visit Dexcom.com/G7 today to get started with Dexcom G7. The
system will be available on Feb. 17.
About Dexcom, Inc.
Dexcom, Inc. empowers people to take control of health through
innovative continuous glucose monitoring systems. Headquartered in
San Diego, California, Dexcom has emerged as a leader of diabetes
care technology. By listening to the needs of users, caregivers and
providers, Dexcom simplifies and improves diabetes management
around the world. For more information about Dexcom, visit
dexcom.com/about-dexcom.
*Fingersticks required for diabetes treatment decisions if
symptoms or expectations do not match readings.
†Under Medicare’s DME fee schedule, reimbursement for CGMs,
using CPT codes E2103 and A4239, is the same, regardless of CGM
brand. Regulation at 42 CFR 410.152(b), stipulates that coinsurance
for items of durable medical equipment is 20% of the allowed
amount. ‡Dexcom G7 can complete warmup within 30 minutes, whereas
other CGM brands require up to an hour or longer. §Compatible smart
devices sold separately. To view a list of compatible smart
devices, visit dexcom.com/compatibility. ||Compared to a prior
generation Dexcom CGM System. An internet connection is required to
send data to Dexcom Clarity. #User must first sync their Dexcom G7
data with the Dexcom Clarity app and consent to share their data
with their healthcare provider. **Separate Follow app and internet
connection required. Users should always confirm readings on the
Dexcom CGM System app or receiver before making treatment
decisions.
1 Dexcom, data on file, 2022. 2 Welsh JB, et al. J Diabetes Sci
Technol. 2022:19322968221099879. 3 Gilbert TR, et al. Diabetes
Technol Ther. 2021;23(S1):S35-S39. 4 Beck RW, et al. JAMA.
2017;317(4):371-378. 5 Beck RW, et al. Ann Intern Med.
2017;167(6):365-374. 6 Martens T, et al. JAMA.
2021;325(22):2262-2272. 7 Managed Markets Insights &
Technology, LLC. MMIT Analytics, June 2022. 8 d&A US Q1 2021
Diabetes Connections Patient Panel Report.2021;69-72. 9 Seagrove
HCP Survey Q1 2021. 2021;65. 10 Shah VN, et al. Diabetes Technol
Ther. 2018;20(6):428-433.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230213005189/en/
Media Contact James McIntosh
619-884-2118 james.mcintosh@dexcom.com
Investor Contact Sean
Christensen 858-203-6657 sean.christensen@dexcom.com
DexCom (NASDAQ:DXCM)
Historical Stock Chart
From Apr 2024 to May 2024
DexCom (NASDAQ:DXCM)
Historical Stock Chart
From May 2023 to May 2024